CovidFranceV1, Main, Exploration, bibRecord, 000778

Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.

Identifieur interne : 000778 ( Main/Exploration ); précédent : 000777; suivant : 000779

Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.

Auteurs : Alimuddin Zumla [Royaume-Uni] ; Fu-Sheng Wang [République populaire de Chine] ; Giuseppe Ippolito [Italie] ; Nicola Petrosillo [Italie] ; Chiara Agrati [Italie] ; Esam I. Azhar [Arabie saoudite] ; Chao Chang [République populaire de Chine] ; Sherif A. El-Kafrawy [Arabie saoudite] ; Mohamed Osman [Royaume-Uni] ; Laurence Zitvogel [France] ; Peter R. Galle [Allemagne] ; Franco Locatelli [Italie] ; Ellen Gorman [Royaume-Uni] ; Carlos Cordon-Cardo [États-Unis] ; Cecilia O'Kane [Royaume-Uni] ; Danny Mcauley [Royaume-Uni] ; Markus Maeurer [Portugal]

Source :

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [ 1878-3511 ] ; 2020.

RBID : pubmed:32425638

Descripteurs français

KwdFr :
- Betacoronavirus (MeSH), Consensus (MeSH), Essais cliniques comme sujet (MeSH), Humains (MeSH), Infections à coronavirus (anatomopathologie), Infections à coronavirus (immunologie), Infections à coronavirus (mortalité), Infections à coronavirus (thérapie), Morbidité (MeSH), Pandémies (MeSH), Pneumopathie virale (anatomopathologie), Pneumopathie virale (immunologie), Pneumopathie virale (mortalité), Pneumopathie virale (thérapie), Transplantation de cellules souches mésenchymateuses (MeSH).
MESH :
- anatomopathologie : Infections à coronavirus, Pneumopathie virale.
- immunologie : Infections à coronavirus, Pneumopathie virale.
- mortalité : Infections à coronavirus, Pneumopathie virale.
- thérapie : Infections à coronavirus, Pneumopathie virale.
- Betacoronavirus, Consensus, Essais cliniques comme sujet, Humains, Morbidité, Pandémies, Transplantation de cellules souches mésenchymateuses.

English descriptors

KwdEn :
- Betacoronavirus (MeSH), Clinical Trials as Topic (MeSH), Consensus (MeSH), Coronavirus Infections (immunology), Coronavirus Infections (mortality), Coronavirus Infections (pathology), Coronavirus Infections (therapy), Humans (MeSH), Mesenchymal Stem Cell Transplantation (MeSH), Morbidity (MeSH), Pandemics (MeSH), Pneumonia, Viral (immunology), Pneumonia, Viral (mortality), Pneumonia, Viral (pathology), Pneumonia, Viral (therapy).
MESH :
- immunology : Coronavirus Infections, Pneumonia, Viral.
- mortality : Coronavirus Infections, Pneumonia, Viral.
- pathology : Coronavirus Infections, Pneumonia, Viral.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, Clinical Trials as Topic, Consensus, Humans, Mesenchymal Stem Cell Transplantation, Morbidity, Pandemics.

Abstract

As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and/or vaccines are found. In search of effective treatments, the global medical, scientific, pharma and funding communities have rapidly initiated over 500 COVID-19 clinical trials on a range of antiviral drug regimens and repurposed drugs in various combinations. A paradigm shift is underway from the current focus of drug development targeting the pathogen, to advancing cellular Host-Directed Therapies (HDTs) for tackling the aberrant host immune and inflammatory responses which underlie the pathogenesis of SARS-CoV-2 and high COVID-19 mortality rates. We focus this editorial specifically on the background to, and the rationale for, the use and evaluation of mesenchymal stromal (Stem) cells (MSCs) in treatment trials of patients with severe COVID-19 disease. Currently, the ClinicalTrials.gov and the WHO Clinical Trials Registry Platform (WHO ICTRP) report a combined 28 trials exploring the potential of MSCs or their products for treatment of COVID-19. MSCs should also be trialed for treatment of other circulating WHO priority Blueprint pathogens such as MERS-CoV which causes upto 34% mortality rates. It's about time funding agencies invested more into development MSCs per se, and also for a range of other HDTs, in combination with other therapeutic interventions. MSC therapy could turn out to be an important contribution to bringing an end to the high COVID-19 death rates and preventing long-term functional disability in those who survive disease.

DOI: 10.1016/j.ijid.2020.05.040
PubMed: 32425638
PubMed Central: PMC7231497

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001215
to stream Main, to step Curation: 001215

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.</title>
<author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Infection, Division of Infection and Immunity, University College London, and National Institutes of Health and Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: a.zumla@ucl.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Infection, Division of Infection and Immunity, University College London, and National Institutes of Health and Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName type="university">University College de Londres</orgName>
</affiliation>
</author>
<author><name sortKey="Wang, Fu Sheng" sort="Wang, Fu Sheng" uniqKey="Wang F" first="Fu-Sheng" last="Wang">Fu-Sheng Wang</name>
<affiliation wicri:level="3"><nlm:affiliation>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. Electronic address: fswang302@163.com.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ippolito, Giuseppe" sort="Ippolito, Giuseppe" uniqKey="Ippolito G" first="Giuseppe" last="Ippolito">Giuseppe Ippolito</name>
<affiliation wicri:level="3"><nlm:affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: giuseppe.ippolito@inmi.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Petrosillo, Nicola" sort="Petrosillo, Nicola" uniqKey="Petrosillo N" first="Nicola" last="Petrosillo">Nicola Petrosillo</name>
<affiliation wicri:level="3"><nlm:affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: nicola.petrosillo@inmi.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Agrati, Chiara" sort="Agrati, Chiara" uniqKey="Agrati C" first="Chiara" last="Agrati">Chiara Agrati</name>
<affiliation wicri:level="3"><nlm:affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: Chiara.Agrati@inmi.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Azhar, Esam I" sort="Azhar, Esam I" uniqKey="Azhar E" first="Esam I" last="Azhar">Esam I. Azhar</name>
<affiliation wicri:level="1"><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: eazhar@kau.edu.sa.</nlm:affiliation>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah</wicri:regionArea>
<wicri:noRegion>Jeddah</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chang, Chao" sort="Chang, Chao" uniqKey="Chang C" first="Chao" last="Chang">Chao Chang</name>
<affiliation wicri:level="3"><nlm:affiliation>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. Electronic address: zhangch302@163.com.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="El Kafrawy, Sherif A" sort="El Kafrawy, Sherif A" uniqKey="El Kafrawy S" first="Sherif A" last="El-Kafrawy">Sherif A. El-Kafrawy</name>
<affiliation wicri:level="1"><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: saelkfrawy@kau.edu.sa.</nlm:affiliation>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah</wicri:regionArea>
<wicri:noRegion>Jeddah</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Osman, Mohamed" sort="Osman, Mohamed" uniqKey="Osman M" first="Mohamed" last="Osman">Mohamed Osman</name>
<affiliation wicri:level="1"><nlm:affiliation>Emerging and Re-Emerging Diseases, University of Khartoum, Sudan and York Biomedical Research Institute, University of York, United Kingdom. Electronic address: mohamed.osman@york.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Emerging and Re-Emerging Diseases, University of Khartoum, Sudan and York Biomedical Research Institute, University of York</wicri:regionArea>
<wicri:noRegion>University of York</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name>
<affiliation wicri:level="1"><nlm:affiliation>Gustave Roussy Cancer Center (GRCC), U1015 INSERM, University Paris Saclay Villejuif Cedex, France. Electronic address: laurence.zitvogel@orange.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Gustave Roussy Cancer Center (GRCC), U1015 INSERM, University Paris Saclay Villejuif Cedex</wicri:regionArea>
<wicri:noRegion>University Paris Saclay Villejuif Cedex</wicri:noRegion>
<wicri:noRegion>University Paris Saclay Villejuif Cedex</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Galle, Peter R" sort="Galle, Peter R" uniqKey="Galle P" first="Peter R" last="Galle">Peter R. Galle</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical Clinic, University Medical Center Mainz, Germany. Electronic address: Galle@uni-mainz.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Medical Clinic, University Medical Center Mainz</wicri:regionArea>
<wicri:noRegion>University Medical Center Mainz</wicri:noRegion>
<wicri:noRegion>University Medical Center Mainz</wicri:noRegion>
<wicri:noRegion>University Medical Center Mainz</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Locatelli, Franco" sort="Locatelli, Franco" uniqKey="Locatelli F" first="Franco" last="Locatelli">Franco Locatelli</name>
<affiliation wicri:level="1"><nlm:affiliation>Dept of Pediatric Hematology and Oncology, IRCCS Ospedale Bambino Gesu, and Sapienza, University of Rome, Italy. Electronic address: franco.locatelli@opbg.net.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Dept of Pediatric Hematology and Oncology, IRCCS Ospedale Bambino Gesu, and Sapienza, University of Rome</wicri:regionArea>
<wicri:noRegion>University of Rome</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gorman, Ellen" sort="Gorman, Ellen" uniqKey="Gorman E" first="Ellen" last="Gorman">Ellen Gorman</name>
<affiliation wicri:level="1"><nlm:affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: egorman03@qub.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast</wicri:regionArea>
<wicri:noRegion>Belfast</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cordon Cardo, Carlos" sort="Cordon Cardo, Carlos" uniqKey="Cordon Cardo C" first="Carlos" last="Cordon-Cardo">Carlos Cordon-Cardo</name>
<affiliation wicri:level="2"><nlm:affiliation>Dept of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: carlos.cordon-cardo@mssm.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dept of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="O Kane, Cecilia" sort="O Kane, Cecilia" uniqKey="O Kane C" first="Cecilia" last="O'Kane">Cecilia O'Kane</name>
<affiliation wicri:level="1"><nlm:affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: c.okane@qub.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast</wicri:regionArea>
<wicri:noRegion>Belfast</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcauley, Danny" sort="Mcauley, Danny" uniqKey="Mcauley D" first="Danny" last="Mcauley">Danny Mcauley</name>
<affiliation wicri:level="1"><nlm:affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: d.f.mcauley@qub.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast</wicri:regionArea>
<wicri:noRegion>Belfast</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Maeurer, Markus" sort="Maeurer, Markus" uniqKey="Maeurer M" first="Markus" last="Maeurer">Markus Maeurer</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical Clinic, University Medical Center Mainz, Germany; Champalimaud Centre for the Unknown, Lisbon, Portugal. Electronic address: markus.maeurer@fundacaochampalimaud.pt.</nlm:affiliation>
<country xml:lang="fr">Portugal</country>
<wicri:regionArea>Medical Clinic, University Medical Center Mainz, Germany; Champalimaud Centre for the Unknown, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32425638</idno>
<idno type="pmid">32425638</idno>
<idno type="doi">10.1016/j.ijid.2020.05.040</idno>
<idno type="pmc">PMC7231497</idno>
<idno type="wicri:Area/Main/Corpus">001215</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001215</idno>
<idno type="wicri:Area/Main/Curation">001215</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001215</idno>
<idno type="wicri:Area/Main/Exploration">001215</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.</title>
<author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Infection, Division of Infection and Immunity, University College London, and National Institutes of Health and Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: a.zumla@ucl.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Infection, Division of Infection and Immunity, University College London, and National Institutes of Health and Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName type="university">University College de Londres</orgName>
</affiliation>
</author>
<author><name sortKey="Wang, Fu Sheng" sort="Wang, Fu Sheng" uniqKey="Wang F" first="Fu-Sheng" last="Wang">Fu-Sheng Wang</name>
<affiliation wicri:level="3"><nlm:affiliation>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. Electronic address: fswang302@163.com.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ippolito, Giuseppe" sort="Ippolito, Giuseppe" uniqKey="Ippolito G" first="Giuseppe" last="Ippolito">Giuseppe Ippolito</name>
<affiliation wicri:level="3"><nlm:affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: giuseppe.ippolito@inmi.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Petrosillo, Nicola" sort="Petrosillo, Nicola" uniqKey="Petrosillo N" first="Nicola" last="Petrosillo">Nicola Petrosillo</name>
<affiliation wicri:level="3"><nlm:affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: nicola.petrosillo@inmi.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Agrati, Chiara" sort="Agrati, Chiara" uniqKey="Agrati C" first="Chiara" last="Agrati">Chiara Agrati</name>
<affiliation wicri:level="3"><nlm:affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: Chiara.Agrati@inmi.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Azhar, Esam I" sort="Azhar, Esam I" uniqKey="Azhar E" first="Esam I" last="Azhar">Esam I. Azhar</name>
<affiliation wicri:level="1"><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: eazhar@kau.edu.sa.</nlm:affiliation>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah</wicri:regionArea>
<wicri:noRegion>Jeddah</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chang, Chao" sort="Chang, Chao" uniqKey="Chang C" first="Chao" last="Chang">Chao Chang</name>
<affiliation wicri:level="3"><nlm:affiliation>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. Electronic address: zhangch302@163.com.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="El Kafrawy, Sherif A" sort="El Kafrawy, Sherif A" uniqKey="El Kafrawy S" first="Sherif A" last="El-Kafrawy">Sherif A. El-Kafrawy</name>
<affiliation wicri:level="1"><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: saelkfrawy@kau.edu.sa.</nlm:affiliation>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah</wicri:regionArea>
<wicri:noRegion>Jeddah</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Osman, Mohamed" sort="Osman, Mohamed" uniqKey="Osman M" first="Mohamed" last="Osman">Mohamed Osman</name>
<affiliation wicri:level="1"><nlm:affiliation>Emerging and Re-Emerging Diseases, University of Khartoum, Sudan and York Biomedical Research Institute, University of York, United Kingdom. Electronic address: mohamed.osman@york.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Emerging and Re-Emerging Diseases, University of Khartoum, Sudan and York Biomedical Research Institute, University of York</wicri:regionArea>
<wicri:noRegion>University of York</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name>
<affiliation wicri:level="1"><nlm:affiliation>Gustave Roussy Cancer Center (GRCC), U1015 INSERM, University Paris Saclay Villejuif Cedex, France. Electronic address: laurence.zitvogel@orange.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Gustave Roussy Cancer Center (GRCC), U1015 INSERM, University Paris Saclay Villejuif Cedex</wicri:regionArea>
<wicri:noRegion>University Paris Saclay Villejuif Cedex</wicri:noRegion>
<wicri:noRegion>University Paris Saclay Villejuif Cedex</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Galle, Peter R" sort="Galle, Peter R" uniqKey="Galle P" first="Peter R" last="Galle">Peter R. Galle</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical Clinic, University Medical Center Mainz, Germany. Electronic address: Galle@uni-mainz.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Medical Clinic, University Medical Center Mainz</wicri:regionArea>
<wicri:noRegion>University Medical Center Mainz</wicri:noRegion>
<wicri:noRegion>University Medical Center Mainz</wicri:noRegion>
<wicri:noRegion>University Medical Center Mainz</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Locatelli, Franco" sort="Locatelli, Franco" uniqKey="Locatelli F" first="Franco" last="Locatelli">Franco Locatelli</name>
<affiliation wicri:level="1"><nlm:affiliation>Dept of Pediatric Hematology and Oncology, IRCCS Ospedale Bambino Gesu, and Sapienza, University of Rome, Italy. Electronic address: franco.locatelli@opbg.net.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Dept of Pediatric Hematology and Oncology, IRCCS Ospedale Bambino Gesu, and Sapienza, University of Rome</wicri:regionArea>
<wicri:noRegion>University of Rome</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gorman, Ellen" sort="Gorman, Ellen" uniqKey="Gorman E" first="Ellen" last="Gorman">Ellen Gorman</name>
<affiliation wicri:level="1"><nlm:affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: egorman03@qub.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast</wicri:regionArea>
<wicri:noRegion>Belfast</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cordon Cardo, Carlos" sort="Cordon Cardo, Carlos" uniqKey="Cordon Cardo C" first="Carlos" last="Cordon-Cardo">Carlos Cordon-Cardo</name>
<affiliation wicri:level="2"><nlm:affiliation>Dept of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: carlos.cordon-cardo@mssm.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dept of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="O Kane, Cecilia" sort="O Kane, Cecilia" uniqKey="O Kane C" first="Cecilia" last="O'Kane">Cecilia O'Kane</name>
<affiliation wicri:level="1"><nlm:affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: c.okane@qub.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast</wicri:regionArea>
<wicri:noRegion>Belfast</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcauley, Danny" sort="Mcauley, Danny" uniqKey="Mcauley D" first="Danny" last="Mcauley">Danny Mcauley</name>
<affiliation wicri:level="1"><nlm:affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: d.f.mcauley@qub.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast</wicri:regionArea>
<wicri:noRegion>Belfast</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Maeurer, Markus" sort="Maeurer, Markus" uniqKey="Maeurer M" first="Markus" last="Maeurer">Markus Maeurer</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical Clinic, University Medical Center Mainz, Germany; Champalimaud Centre for the Unknown, Lisbon, Portugal. Electronic address: markus.maeurer@fundacaochampalimaud.pt.</nlm:affiliation>
<country xml:lang="fr">Portugal</country>
<wicri:regionArea>Medical Clinic, University Medical Center Mainz, Germany; Champalimaud Centre for the Unknown, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</title>
<idno type="eISSN">1878-3511</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (MeSH)</term>
<term>Clinical Trials as Topic (MeSH)</term>
<term>Consensus (MeSH)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (mortality)</term>
<term>Coronavirus Infections (pathology)</term>
<term>Coronavirus Infections (therapy)</term>
<term>Humans (MeSH)</term>
<term>Mesenchymal Stem Cell Transplantation (MeSH)</term>
<term>Morbidity (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (immunology)</term>
<term>Pneumonia, Viral (mortality)</term>
<term>Pneumonia, Viral (pathology)</term>
<term>Pneumonia, Viral (therapy)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Betacoronavirus (MeSH)</term>
<term>Consensus (MeSH)</term>
<term>Essais cliniques comme sujet (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (anatomopathologie)</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Infections à coronavirus (mortalité)</term>
<term>Infections à coronavirus (thérapie)</term>
<term>Morbidité (MeSH)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (anatomopathologie)</term>
<term>Pneumopathie virale (immunologie)</term>
<term>Pneumopathie virale (mortalité)</term>
<term>Pneumopathie virale (thérapie)</term>
<term>Transplantation de cellules souches mésenchymateuses (MeSH)</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>Clinical Trials as Topic</term>
<term>Consensus</term>
<term>Humans</term>
<term>Mesenchymal Stem Cell Transplantation</term>
<term>Morbidity</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term>
<term>Consensus</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Morbidité</term>
<term>Pandémies</term>
<term>Transplantation de cellules souches mésenchymateuses</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and/or vaccines are found. In search of effective treatments, the global medical, scientific, pharma and funding communities have rapidly initiated over 500 COVID-19 clinical trials on a range of antiviral drug regimens and repurposed drugs in various combinations. A paradigm shift is underway from the current focus of drug development targeting the pathogen, to advancing cellular Host-Directed Therapies (HDTs) for tackling the aberrant host immune and inflammatory responses which underlie the pathogenesis of SARS-CoV-2 and high COVID-19 mortality rates. We focus this editorial specifically on the background to, and the rationale for, the use and evaluation of mesenchymal stromal (Stem) cells (MSCs) in treatment trials of patients with severe COVID-19 disease. Currently, the ClinicalTrials.gov and the WHO Clinical Trials Registry Platform (WHO ICTRP) report a combined 28 trials exploring the potential of MSCs or their products for treatment of COVID-19. MSCs should also be trialed for treatment of other circulating WHO priority Blueprint pathogens such as MERS-CoV which causes upto 34% mortality rates. It's about time funding agencies invested more into development MSCs per se, and also for a range of other HDTs, in combination with other therapeutic interventions. MSC therapy could turn out to be an important contribution to bringing an end to the high COVID-19 death rates and preventing long-term functional disability in those who survive disease.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32425638</PMID>
<DateCompleted><Year>2020</Year>
<Month>07</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>08</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>96</Volume>
<PubDate><Year>2020</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title>
<ISOAbbreviation>Int. J. Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.</ArticleTitle>
<Pagination><MedlinePgn>431-439</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1201-9712(20)30347-7</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2020.05.040</ELocationID>
<Abstract><AbstractText>As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and/or vaccines are found. In search of effective treatments, the global medical, scientific, pharma and funding communities have rapidly initiated over 500 COVID-19 clinical trials on a range of antiviral drug regimens and repurposed drugs in various combinations. A paradigm shift is underway from the current focus of drug development targeting the pathogen, to advancing cellular Host-Directed Therapies (HDTs) for tackling the aberrant host immune and inflammatory responses which underlie the pathogenesis of SARS-CoV-2 and high COVID-19 mortality rates. We focus this editorial specifically on the background to, and the rationale for, the use and evaluation of mesenchymal stromal (Stem) cells (MSCs) in treatment trials of patients with severe COVID-19 disease. Currently, the ClinicalTrials.gov and the WHO Clinical Trials Registry Platform (WHO ICTRP) report a combined 28 trials exploring the potential of MSCs or their products for treatment of COVID-19. MSCs should also be trialed for treatment of other circulating WHO priority Blueprint pathogens such as MERS-CoV which causes upto 34% mortality rates. It's about time funding agencies invested more into development MSCs per se, and also for a range of other HDTs, in combination with other therapeutic interventions. MSC therapy could turn out to be an important contribution to bringing an end to the high COVID-19 death rates and preventing long-term functional disability in those who survive disease.</AbstractText>
<CopyrightInformation>Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zumla</LastName>
<ForeName>Alimuddin</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Infection, Division of Infection and Immunity, University College London, and National Institutes of Health and Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: a.zumla@ucl.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Fu-Sheng</ForeName>
<Initials>FS</Initials>
<AffiliationInfo><Affiliation>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. Electronic address: fswang302@163.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ippolito</LastName>
<ForeName>Giuseppe</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: giuseppe.ippolito@inmi.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Petrosillo</LastName>
<ForeName>Nicola</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: nicola.petrosillo@inmi.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Agrati</LastName>
<ForeName>Chiara</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: Chiara.Agrati@inmi.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Azhar</LastName>
<ForeName>Esam I</ForeName>
<Initials>EI</Initials>
<AffiliationInfo><Affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: eazhar@kau.edu.sa.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chang</LastName>
<ForeName>Chao</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. Electronic address: zhangch302@163.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>El-Kafrawy</LastName>
<ForeName>Sherif A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo><Affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: saelkfrawy@kau.edu.sa.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Osman</LastName>
<ForeName>Mohamed</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Emerging and Re-Emerging Diseases, University of Khartoum, Sudan and York Biomedical Research Institute, University of York, United Kingdom. Electronic address: mohamed.osman@york.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zitvogel</LastName>
<ForeName>Laurence</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Center (GRCC), U1015 INSERM, University Paris Saclay Villejuif Cedex, France. Electronic address: laurence.zitvogel@orange.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Galle</LastName>
<ForeName>Peter R</ForeName>
<Initials>PR</Initials>
<AffiliationInfo><Affiliation>Medical Clinic, University Medical Center Mainz, Germany. Electronic address: Galle@uni-mainz.de.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Locatelli</LastName>
<ForeName>Franco</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Dept of Pediatric Hematology and Oncology, IRCCS Ospedale Bambino Gesu, and Sapienza, University of Rome, Italy. Electronic address: franco.locatelli@opbg.net.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gorman</LastName>
<ForeName>Ellen</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: egorman03@qub.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cordon-Cardo</LastName>
<ForeName>Carlos</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Dept of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: carlos.cordon-cardo@mssm.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>O'Kane</LastName>
<ForeName>Cecilia</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: c.okane@qub.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McAuley</LastName>
<ForeName>Danny</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: d.f.mcauley@qub.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Maeurer</LastName>
<ForeName>Markus</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Medical Clinic, University Medical Center Mainz, Germany; Champalimaud Centre for the Unknown, Lisbon, Portugal. Electronic address: markus.maeurer@fundacaochampalimaud.pt.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Canada</Country>
<MedlineTA>Int J Infect Dis</MedlineTA>
<NlmUniqueID>9610933</NlmUniqueID>
<ISSNLinking>1201-9712</ISSNLinking>
</MedlineJournalInfo>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009017" MajorTopicYN="N">Morbidity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>05</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32425638</ArticleId>
<ArticleId IdType="doi">10.1016/j.ijid.2020.05.040</ArticleId>
<ArticleId IdType="pii">S1201-9712(20)30347-7</ArticleId>
<ArticleId IdType="pmc">PMC7231497</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
<li>Arabie saoudite</li>
<li>France</li>
<li>Italie</li>
<li>Portugal</li>
<li>Royaume-Uni</li>
<li>République populaire de Chine</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
<li>Latium</li>
<li>État de New York</li>
</region>
<settlement><li>Londres</li>
<li>Pékin</li>
<li>Rome</li>
</settlement>
<orgName><li>University College de Londres</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name>
</region>
<name sortKey="Gorman, Ellen" sort="Gorman, Ellen" uniqKey="Gorman E" first="Ellen" last="Gorman">Ellen Gorman</name>
<name sortKey="Mcauley, Danny" sort="Mcauley, Danny" uniqKey="Mcauley D" first="Danny" last="Mcauley">Danny Mcauley</name>
<name sortKey="O Kane, Cecilia" sort="O Kane, Cecilia" uniqKey="O Kane C" first="Cecilia" last="O'Kane">Cecilia O'Kane</name>
<name sortKey="Osman, Mohamed" sort="Osman, Mohamed" uniqKey="Osman M" first="Mohamed" last="Osman">Mohamed Osman</name>
</country>
<country name="République populaire de Chine"><noRegion><name sortKey="Wang, Fu Sheng" sort="Wang, Fu Sheng" uniqKey="Wang F" first="Fu-Sheng" last="Wang">Fu-Sheng Wang</name>
</noRegion>
<name sortKey="Chang, Chao" sort="Chang, Chao" uniqKey="Chang C" first="Chao" last="Chang">Chao Chang</name>
</country>
<country name="Italie"><region name="Latium"><name sortKey="Ippolito, Giuseppe" sort="Ippolito, Giuseppe" uniqKey="Ippolito G" first="Giuseppe" last="Ippolito">Giuseppe Ippolito</name>
</region>
<name sortKey="Agrati, Chiara" sort="Agrati, Chiara" uniqKey="Agrati C" first="Chiara" last="Agrati">Chiara Agrati</name>
<name sortKey="Locatelli, Franco" sort="Locatelli, Franco" uniqKey="Locatelli F" first="Franco" last="Locatelli">Franco Locatelli</name>
<name sortKey="Petrosillo, Nicola" sort="Petrosillo, Nicola" uniqKey="Petrosillo N" first="Nicola" last="Petrosillo">Nicola Petrosillo</name>
</country>
<country name="Arabie saoudite"><noRegion><name sortKey="Azhar, Esam I" sort="Azhar, Esam I" uniqKey="Azhar E" first="Esam I" last="Azhar">Esam I. Azhar</name>
</noRegion>
<name sortKey="El Kafrawy, Sherif A" sort="El Kafrawy, Sherif A" uniqKey="El Kafrawy S" first="Sherif A" last="El-Kafrawy">Sherif A. El-Kafrawy</name>
</country>
<country name="France"><noRegion><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name>
</noRegion>
</country>
<country name="Allemagne"><noRegion><name sortKey="Galle, Peter R" sort="Galle, Peter R" uniqKey="Galle P" first="Peter R" last="Galle">Peter R. Galle</name>
</noRegion>
</country>
<country name="États-Unis"><region name="État de New York"><name sortKey="Cordon Cardo, Carlos" sort="Cordon Cardo, Carlos" uniqKey="Cordon Cardo C" first="Carlos" last="Cordon-Cardo">Carlos Cordon-Cardo</name>
</region>
</country>
<country name="Portugal"><noRegion><name sortKey="Maeurer, Markus" sort="Maeurer, Markus" uniqKey="Maeurer M" first="Markus" last="Maeurer">Markus Maeurer</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000778 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000778 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32425638
   |texte=   Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32425638" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidFranceV1

This area was generated with Dilib version V0.6.37.
Data generation: Tue Oct 6 23:31:36 2020. Site generation: Fri Feb 12 22:48:37 2021

	Serveur d'exploration sur la COVID en France
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID en France

Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.

Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki